Adents and Microsoft pool resources to create new cloud platform
October 27, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Adents, EU, France, Microsoft
Adents, a French software developer for unique production identification and ‘Track & Trace’ solutions, and Microsoft have developed, with an …
Sanofi forms new alliance to fight zika in Brazil
October 27, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Sanofi, Zika
Sanofi has teamed up with Brazilian research institute Fiocruz to accelerate development of a zika vaccine.This is another step in …
Teva team up with IBM to tackle two challenges facing the pharma industry
October 27, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cloud Computing, Teva Pharmaceutical, asthma, ibm
Teva Pharmaceuticals and IBM have announced a partnership that will use IBM Watson Health Cloud with the aim of finding …
Oxford Genetics gets further £1 million investment boost
October 27, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Mercia Technologies, Oxford Genetics, synthetic biology
Warwickshire-based biotech Mercia Technologies has injected a further £1 million into synthetic biology- specialist Oxford Genetics, bringing their total investment …
AZ reveals compelling PhIII data for ovarian cancer treatment
October 26, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AZ, AstraZeneca, lynparza
AstraZeneca has revealed new results from a Phase III trial investigating the efficacy of its Lynparza drug as a monotherapy …
Price hiking: US pharma’s elephant in the room
October 26, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bernie Sanders, Martin Shkreli, Mylan, Sanofi, Turing Pharmaceuticals, price hikes
Mylan’s recent EpiPen price inflation scandal has reignited a seemingly never-ending debate on the power of drug companies to charge …
The November Issue of Pharmafocus is now live!
October 26, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Pharmafocus, features, latest news, news
The latest issue of Pharmafocus is now live and ready to be read! We’ve taken the opportunity to cover some of …
Nordic Nanovector to collaborate with Heidelberg Pharma to develop leukaemia treatment
October 26, 2016Research and Development Nordic Nanovector, WILEX, heidelberg pharma, leukaemia
Nordic Nanovector has announced that they have formed a partnership with WILEX subsidiary, Heidelberg Pharma. Heidelberg Pharma specialises in the …
NHS suppliers investigated over 1000% price hikes
October 26, 2016Research and Development, Sales and Marketing NHS, price hikes
The Competition and Marketing Authority has launched an investigation into a number of drug companies following claims that 32 drugs …
Backlash over testosterone replacement drugs builds with FDA warnings
October 26, 2016Research and Development FDA, FDA Warning, low t, prescription testosterone
The backlash against the over-prescription of ‘testosterone boosters’ continues in the US, with the FDA taking action to add clear …
New UK research illuminates new developments for anticancer treatment
October 26, 2016Research and Development anticancer
New research from the University of Huddersfield has shed light on a new lab technique which could aid in the …
MSD’s Keytruda given first FDA approval for first line treatment
October 25, 2016Manufacturing and Production BMS, MSD, NSCLC, keytruda, opdivo
MSD, known as Merck in the US, has scored a big success in treating non-small cell lung cancer (NSCLC), with …
Novartis rides out fiscal hardship to beat Q3 forecasts
October 25, 2016Manufacturing and Production, Sales and Marketing Entresto, Gleevec, Novartis
Novartis has beaten its third-quarter sales projections, announcing that new product growth and cost cuts managed to carry the company …
Dr Reddy’s Laboratories profits drop 60%
October 25, 2016Manufacturing and Production, Sales and Marketing Dr Reddy's Laboratories
Indian pharmaceutical firm Dr Reddy’s Laboratories has suffered a drop of 60.12% in consolidated net profit for the September quarter. …
EMA opens clinical trial data to public
October 25, 2016Manufacturing and Production Amgen, AstraZeneca, EMA, EU, Kyprolis, clinical reports, clinical trials
The European Medicine Agency has begun to release to the public data on clinical trial via their own website. The …
Concordia founder resigns and will step down once replacement found
October 25, 2016Manufacturing and Production CEO, Concordia, Mark Thompson, Valeant
Concordia International Corp., the Ontario-based company, has announced that its founder, Chairman and Chief Executive Officer, Mark Thompson, will leave …
Colombian pharma market to break $7 billion by 2020
October 24, 2016Business Services, Manufacturing and Production, Research and Development, Sales and Marketing Colombia, market report
According to new findings from GlobalData, the Colombian pharmaceutical market is due to grow from $5 billion in 2015 to …
FDA accepts another Opdivo indication for priority review
October 24, 2016Sales and Marketing BMS, Bristol-Myers Squibb, FDA, opdivo
The FDA has accepted a supplemental Biologics License Application (sBLA) for Bristol-Myers Squibb’s Opdivo for treatment of locally advanced unresectable …
MSD’s Keytruda early success ends trial early
October 24, 2016Sales and Marketing MSD, Merck, Roche, keytruda, opdivo, tecentriq
MSD, known as Merck in the US, ended their Phase III trial of Keytruda for treatment of advanced urothelial cancer …
Phase III depression trial success for Alkermes
October 24, 2016Research and Development, Sales and Marketing ALKS 5461, Alkermes, major depressive disorder
Biopharma company Alkermes has announced the success of its ALKS 5461 treatment in a Phase III study for the treatment …
Latest content
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
Danish medical cannabis use rises as regulator reports no new safety signals
